Inventor · disambiguated record
Dennis Slamon
Also filed as: SLAMON DENNIS · SLAMON DENNIS J · SLAMON DENNIS JOSEPH
23 granted patents·24 pending applications·1,443 citations·filing 1984–2025
96Inventor score
Files withUNIV CALIFORNIA35CALIFORNIA INST OF TECHN4BRISTOL MYERS SQUIBB CO21200 PHARMA LLC1SLAMON DENNIS J1
Top patents by PatentIndex Score
47 records- 0197US4968603ADetermination of status in neoplastic diseaseUNIV CALIFORNIA·Filed 1986·Granted Nov 6, 1990·457 cites·22 claims
- 0297US4699877AMethods and compositions for detecting human tumorsUNIV CALIFORNIA·Filed 1984·Granted Oct 13, 1987·187 cites·22 claims
- 0395US5990141ATreatment of platelet derived growth factor related disorders such as cancersSUGEN INC·Filed 1995·Granted Nov 23, 1999·189 cites·20 claims
- 0491US12065489B2Claudin-6 antibodies and drug conjugatesUNIV CALIFORNIA·Filed 2022·Granted Aug 20, 2024·2 cites·59 claims
- 0591US5846749AQuantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determinationUNIV CALIFORNIA·Filed 1994·Granted Dec 8, 1998·145 cites·12 claims
- 0690US7125680B2Methods and materials for characterizing and modulating interaction between heregulin and HER3UNIV CALIFORNIA·Filed 2002·Granted Oct 24, 2006·33 cites·4 claims
- 0790US6893837B2Frozen tissue microarray technology for analysis RNA, DNA, and proteinsUNIV CALIFORNIA·Filed 2004·Granted May 17, 2005·49 cites·5 claims
- 0887US11834499B1Claudin18 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2022·Granted Dec 5, 2023·1 cites·99 claims
- 0987US6767541B2HER-2/neu overexpression abrogates growth inhibitory pathwaysUNIV CALIFORNIA·Filed 2001·Granted Jul 27, 2004·37 cites·19 claims
- 1087US6326148B1Detection of copy number changes in colon cancerUNIV CALIFORNIA·Filed 1999·Granted Dec 4, 2001·204 cites·25 claims
- 1185USRE35491EMethods and compositions for detecting human tumorsUNIV CALIFORNIA·Filed 1989·Granted Apr 8, 1997·58 cites·9 claims
- 1284US7314916B2Methods and materials for characterizing and modulating interaction between heregulin and HER3UNIV CALIFORNIA·Filed 2006·Granted Jan 1, 2008·7 cites·4 claims
- 1381US2025333501A1Claudin 4 and claudin 9 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 1480US8007995B2Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancersBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Aug 30, 2011·13 cites·15 claims
- 1580US2025066469A1Claudin-6 antibodies and drug conjugatesUNIV CALIFORNIA·Filed 2024·Application pending·0 cites
- 1679US6696271B2Frozen tissue microarray technology for analysis of RNA, DNA, and proteinsUNIV CALIFORNIA·Filed 2001·Granted Feb 24, 2004·18 cites·6 claims
- 1779US2024400674A1Claudin 4 and claudin 9 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 1877US4918162AAssays and antibodies for N-MYC proteinsUNIV CALIFORNIA·Filed 1988·Granted Apr 17, 1990·38 cites·3 claims
- 1974US2024390374A1Mocetinostat in combination with chemotherapy to treat rhabdomyosarcomaUNIV CALIFORNIA·Filed 2024·Application pending·0 cites
- 2072US2022372134A1Claudin6 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2171US6770477B1Differentially expressed genes associated with HER-2/neu overexpressionUNIV CALIFORNIA·Filed 2000·Granted Aug 3, 2004·4 cites·13 claims
- 2266US12403202B2Dosage of claudin-6 conjugates for cancer treatmentUNIV CALIFORNIA·Filed 2024·Granted Sep 2, 2025·0 cites·27 claims
- 2365US12345709B2CLAUDIN18 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2020·Granted Jul 1, 2025·0 cites·15 claims
- 2463US2020291111A1Claudin6 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2018·Application pending·0 cites
- 2563US2022280510A1Mocetinostat in combination with chemotherapy to treat rhabdomyosarcomaUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2663US2022162299A1Claudin-6 antibodies and drug conjugatesUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 2762US2016138114A1Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in CancerUNIV CALIFORNIA·Filed 2014·Application pending·0 cites
- 2859US2019048424A1Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in CancerUNIV CALIFORNIA·Filed 2018·Application pending·0 cites
- 2957US2025042992A1Dlk1 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 3057US2025051437A1Cdh17 antibodies and methods of treating cancerUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 3156US2017369950A1Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in CancerUNIV CALIFORNIA·Filed 2017·Application pending·0 cites
- 3254US2025136582A1Select kras g12c inhibitors and uses thereof1200 PHARMA LLC·Filed 2022·Application pending·0 cites
- 3350US2011166154A1Identification of predictive markers of response to dasatinib in human colon cancerBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 3450US2019292605A1Biomarkers of Response to Cyclin D-CDK4/6 Targeted Therapies in CancerUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 3549US12486280B2CDK inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2019·Granted Dec 2, 2025·0 cites·23 claims
- 3649US2021355545A1Methods and materials for assessing and treating cancerUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 3749US2005079508A1Constraints-based analysis of gene expression dataFiled 2003·Application pending·0 cites
- 3847US12428416B2ERK inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2019·Granted Sep 30, 2025·0 cites·20 claims
- 3947US2022177583A1Claudin-6 bispecific antibodiesUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 4046US2023116602A1Mcl1 inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2020·Application pending·0 cites
- 4144US7537905B2Amplified and overexpressed gene in colorectal cancersUNIV CALIFORNIA·Filed 2003·Granted May 26, 2009·0 cites·15 claims
- 4244US6929910B2Diagnostic and therapeutic methods using the H37 tumor suppressor geneUNIV CALIFORNIA·Filed 2001·Granted Aug 16, 2005·0 cites·9 claims
- 4344US2022227738A1Kras g12c inhibitors and uses thereofCALIFORNIA INST OF TECHN·Filed 2020·Application pending·0 cites
- 4443US2017067116A1Biomarkers of Response to Cyclin D-CDK4/6 Targeted Therapies in CancerUNIV CALIFORNIA·Filed 2015·Application pending·0 cites
- 4542US2006147930A1Amplified and overexpressed gene in colorectal cancersSLAMON DENNIS J·Filed 2004·Application pending·0 cites
- 4632US2008318212A1Orphan Receptor Tyrosine Kinase as a Target in Breast CancerWILSON CINDY A·Filed 2005·Application pending·0 cites
- 4731US5063150ARetroviral polypeptides associated with human cellular transformationUNIV CALIFORNIA·Filed 1985·Granted Nov 5, 1991·1 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when Dennis Slamon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →